Keith Chappell on a bivalent recombinant vaccine for COVID-19

Dr Keith Chappell discusses the bivalent recombinant vaccine for
COVID-19 following the study by Dayan and colleagues, with focus
on vaccine access, variants and boosters, tolerability and side
effects, as well as hopes for future trials.


Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv